BioNTech
Biotechnology company from Germany
BNTX Nasdaq
ISIN US09075V1026 SEC CIK 1776985 LEI 894500UZJ5LG1F8J1U58
Follow BioNTech
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €2.9B | −€1.1B |
| FY24 | €2.8B | −€665.3M |
| FY23 | €3.8B | €930.3M |
| FY22 | €17.3B | €9.4B |
| FY21 | €19B | €10.3B |
| FY20 | €482.3M | €15.2M |
| FY19 | €108.6M | −€179.1M |
| FY18 | €127.6M | −€48M |
| FY17 | €61.6M | −€85.7M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 77.6% | −49% | −39.6% |
| FY24 | 80.3% | −47.8% | −24.2% |
| FY23 | 84.3% | 18.1% | 24.4% |
| FY22 | 82.7% | 73% | 54.5% |
| FY21 | 84.7% | 80.5% | 54.2% |
| FY20 | 87.7% | −17.1% | 3.2% |
| FY19 | 84% | −167.1% | −164.9% |
| FY18 | 89.3% | −42.2% | −37.6% |
| FY17 | 84.9% | −99.5% | −139.1% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | €280.9M |
| FY24 | −€78.8M |
| FY23 | €5.1B |
| FY22 | €13.2B |
| FY21 | €762.2M |
| FY20 | −€79.5M |
| FY19 | −€237.1M |
| FY18 | −€88.8M |
| FY17 | −€76.9M |
| FY16 | - |
Show the numbers
| Year | Dividends |
|---|---|
| FY25 | - |
| FY24 | €0 |
| FY23 | €0 |
| FY22 | €484.3M |
| FY21 | €0 |
| FY20 | €0 |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
- BioNTech
- Healthcare median
Show the numbers
| Year | BioNTech | Healthcare median |
|---|---|---|
| FY25 | −39.6% | −30.6% |
| FY24 | −24.2% | −47% |
| FY23 | 24.4% | −58% |
| FY22 | 54.5% | −80.4% |
| FY21 | 54.2% | −71.9% |
| FY20 | 3.2% | −62.2% |
| FY19 | −164.9% | −46.3% |
| FY18 | −37.6% | −49.6% |
| FY17 | −139.1% | −45.9% |
| FY16 | - | −36% |